Barinthus Biotherapeutics plc
Price
FilingsNewest: 8-K, Agreement endedSep 9 →InsidersNo open-market buys or sales.→HoldersM&G 12.7%HSG Holding 3.5%GLR Partners 3.0%→
From the filings
Figures
- Revenue
- $0.00last 12 months
- Net income
- −$41.8Mlast 12 months
- Operating cash flow
- −$36.4Mlast 12 months
- Cash and equivalents
- $59.3Mat the last balance sheet
- Shares outstanding
- 40.8M shareson issue